Compare F.N.B. Corporation Common Stock (FNB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs Novo Nordisk A/S — how do they compare? F.N.B. Corporation Common Stock trades at $16.91 (market cap $6.07B), while Novo Nordisk A/S trades at $38.63 (market cap $169.08B). The key difference: Novo Nordisk A/S is far larger — about 27.9× F.N.B. Corporation Common Stock's market cap, and Novo Nordisk A/S pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Novo Nordisk A/S for 116 Days on average.
| FNB | NVO | |
|---|---|---|
Market Cap | $6.07B | $169.08B |
Volume | 5,600,609 | 9,259,152 |
Sector | Financials | Health |
52-Week High | $19.49 | $63.98 |
52-Week Low | $14.65 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $10.61B | $183.28B |
Dividend Yield | 3.05% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.
The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
